Market Overview

Bristol-Myers Analyst Says 'Big 7' Pipeline Assets Hold $15B In Peak Sales Potential

Share:
Bristol-Myers Analyst Says 'Big 7' Pipeline Assets Hold $15B In Peak Sales Potential

Biopharma companies are among the most resilient among sectors during the coronavirus pandemic, and one large-cap biopharma has a slew of products in its pipeline that have blockbuster potential, according to BofA Securities. 

Brace For Bristol-Myers' ‘Big 7'

Bristol-Myers Squibb Co's (NYSE: BMY) new product cycle consists of seven products across various higher-profile markets like hematology/oncology and immunology and inflammation, or I&I, analyst Geoff Meacham said in a recent note.

Following the Celgene deal, Bristol-Myers has one of the best portfolios across the biopharma industry, the analyst said.

BofA is cognizant of the loss of exclusivity related to Bristol-Myers' blood cancer drug Revlimid, which is expected to go off patent in 2022/2023. Yet investors aren't fully appreciating the upside potential from the portfolio, Meacham said. 

"We think the 'Big 7' new product cycle could exceed Revlimid's $12B franchise, and collectively we see potential for >$15B in peak sales."  

Most of the company's assets are already derisked and have an opportunity for a meaningful inflection point heading into near-term commercial launches, the analyst said. 

BofA highlighted the following seven pipeline assets: 

Inberic

  • Generic name: fedratinib
  • Drug Type: selective oral JAK2 inhibitor
  • Status: Approved in 2019; initial launch underway
  • Indication(s): treatment option for myelofibrosis patients who relapsed or are intolerant to Incyte Corporation's (NASDAQ: INCY) Jakafi
  • BofA's Peak Potential Estimate: About $750 million

See also: The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive

Rebloyzl

  • Generic name: luspatercept
  • Drug Type: erythroid maturation agent
  • Status: initially approved in November 2019
  • Indication(s): treatment of anemia in adults with beta thalassemia and also anemia in adults with lower risk myelodysplastic syndrome
  • BofA's Peak Potential Estimate: over $2 billion in both indications

Zeposia

  • Generic name: ozanimod
  • Drug Type: oral S1P-r modulator
  • Status: approved in March 2020 for multiple sclerosis; launch scheduled for June 1
  • Indication(s): Apart from multiple sclerosis, it is being evaluated in late-stage studies for ulcerative colitis
  • BofA's Peak Potential Estimate: $3.5 billion for both indications

JCAR017

  • Generic name: liso-cel
  • Drug Type: lead chimeric antigen receptor T-cell product candidate
  • Status: in review, with a PDUFA date of mid-November
  • Indication(s): diffuse large B-cell lymphoma
  • BofA's Peak Potential Estimate: $2.5 billion for both indications

bb2121

  • Generic name: ide-cel
  • Drug Type: BCMA-targeted CAR-T therapy developed along with bluebird bio Inc (NASDAQ: BLUE) Status: received a refuse-to-file letter from the FDA; refiling expected by July 2020 and approval likely in the first half of 2021 
  • Indication(s): relapsed/refractory multiple myeloma
  • BofA's Peak Potential Estimate: over $2.5 billion

CC-486

  • Generic name: CC-486
  • Drug Type: oral hypomethylating agent/oral formulation of Vidaza
  • Status: PDUFA date of early September
  • Indication(s): first-line acute myeloid leukemia
  • BofA's Peak Potential Estimate: $1.5 billion

TYKT

  • Generic name: BMS-'165
  • Drug Type: oral TYK2 or tyrosine kinase 2 inhibitor
  • Status: registrational data expected by year-end and potential filing by the first half of 2021 Indication(s): evaluated in various I&I indications, with a lead phase 3 program in psoriasis being the major value driver
  • BofA's Peak Potential Estimate: $2.5 billion

Bristol-Myers Rating & Price Target

BofA rates Bristol-Myers a Buy and $80 price target, suggesting roughly 30% upside from current levels.

BMY Price Action

At last check, Bristol-Myers shares were slipping by 0.58% to $59.98. 

Related Link: AstraZeneca Receives Over $1B In BARDA Funding For Coronavirus Vaccine

Latest Ratings for BMY

DateFirmActionFromTo
May 2020CFRAMaintainsBuy
Apr 2020B of A SecuritiesMaintainsBuy
Mar 2020Societe GeneraleDowngradesBuyHold

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

 

Related Articles (BMY)

View Comments and Join the Discussion!

Posted-In: BofA Securities Geoff MeachamAnalyst Color Biotech Price Target Reiteration Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

StockFirmActionPT
BKHMizuhoMaintains70.0
JOBAlliance Global PartnersUpgrades2.5
RARECanaccord GenuityMaintains91.0
TTDOppenheimerMaintains450.0
PYPLWedbushMaintains200.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com